Subscribe We look forward to unblinding the top-line datain August 2009 and expect to have data
By Admin
"We look forward to unblinding the top-line datain August 2009 and expect to have data from the open label extension availableby the end of the year. Intotal, 282 of 326 patients (or 86.5%) completed the 12-week double-blind phaseof the study and were eligible to enroll in the open label extension phase. Atotal of 253 (or 89.7%) of eligible patients elected to enroll in the 12-weekopen label safety extension. The low overall rate of discontinuation in theblinded phase and high percentage of eligible patients choosing to enroll in theoptional open label extension phase compare favorably with previous experience. Theprimary objective of the open-label extension study is to assess the long-termsafety of Zenvia (dextromethorphan/quinidine [DM/Q]) in patients diagnosed withpseudobulbar affect (PBA) resulting from an underlying neurological disorder.
Topline Data from Double-Blind Phase of STAR Trial Expected in AugustALISO VIEJO, Calif.--(Business Wire)--AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the open labelextension of the confirmatory Phase III STAR trial is now fully enrolled. Photos/Multimedia Gallery Available: http:// PartnersMedia:USFlorencia Panizza, +orCourtney Goldstein, +orUKBGC PartnersAlexandra Walker, +44 20 7894 Copyright Business Wire 2009. This discussion isprovided to increase the understanding of, and should be read in conjunctionwith, our Consolidated Financial Statements and the accompanying Notes theretoincluded elsewhere in our most recent Form 10-K. The information included herein is given as of thefiling date of our most recent Form 10-K with the SEC, and future events orcircumstances could differ significantly from these forward-looking statements.The Company does not undertake to publicly update or revise any forward-lookingstatements, whether as a result of new information, future events or otherwise.Our discussions in financial releases often summarize the significant factorsaffecting our results of operations and financial condition.
The foregoing risks anduncertainties, as well as those risks discussed under the heading "Item7A-Quantitative and Qualitative Disclosures About Market Risk" and elsewhere inour most recent 10-K, may cause actual results to differ materially from theforward-looking statements. ("BGC Holdings") limited partnership interests or other equity interests inour subsidiaries, including from Cantor, our executive officers, and ouremployees; and the risks and other factors described herein under the heading"Item 1A-Risk Factors" in most recent Form 10-K filed with the SEC on March 16,2009, and as amended in any subsequent filings. Ouractual results and the outcome and timing of certain events may differsignificantly from the expectations discussed in the forward-looking statements.Factors that might cause or contribute to such a discrepancy include, but arenot limited to: our relationship with Cantor Fitzgerald, L.P. For example,words such as "may," "will," "should," "estimates," "predicts," "potential,""continue," "strategy," "believes," "anticipates," "plans," "expects," "intends"and similar expressions are intended to identify forward-looking statements. Any statements contained herein that are not statements ofhistorical fact may be deemed to be forward-looking statements.
Discussion of Forward-Looking Statements by BGC PartnersThe information in this release contains forward-looking statements within themeaning of Section 27A of the Securities Act of 1933, as amended, and Section21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act").Such statements are based upon current expectations that involve risks anduncertainties. Working closely with our experiencedtechnology team, preferred vendors can connect directly to BGC`s ApplicationProgramming Interface (API) to give their customers fast access to BGC`s marketfor US Treasuries and other electronically traded products. BGC Partners` preferred vendors are chosen with the aim of supporting andenhancing the range of complex strategies demanded by today`s traders, and tooffer trading access to global pools of liquidity for the most sophisticatedtraders on both the buy-side and sell-side. For more information, visit http:// The Company`s corporate address is: BGC Partners,Inc., 499 Park Avenue, New York, New York 10022. The media, analysts, andinvestors can also subscribe to BGC Partners` investor "Email Alerts" at the"Investor Relations" section of http:// About BGC Partners` Preferred Vendor ProgramBGC Partners` `preferred vendor program` was established in 2009 to offerselected network providers and independent software vendors direct access toBGC`s proprietary trading platform, eSpeed.